Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 multi-dose, dose-escalation study of ALN-TTR02 in transthyretin-mediated amyloidosis
2012-000467-24Phase 2Completed
- Sponsor
- Alnylam Pharmaceuticals
- Start
- Feb 2012
- Modality
- Gene Therapies, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of patisiran in transthyretin amyloidosis (ATTR) and amyloid cardiomyopathy, sponsored by Alnylam Pharmaceuticals. Primary endpoint: Safety and tolerability of multiple doses of ALN-TTR02. Started Feb 2012; status: completed.
02
Drugs
patisiran
03
Conditions
transthyretin amyloidosis (ATTR)amyloid cardiomyopathy
Beyond the preview
Go deeper on 2012-000467-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000467-24.